57 / 74 · 0:54 · Original AXON film
Mazdutide
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
GLP-1 and glucagon research
Mazdutide activates GLP-1 and glucagon receptors. Its GLORY-1 study offers a useful example of why the trial population belongs alongside the result. [1]
GLORY-1 | 610 adults in China
The 2025 randomized, placebo-controlled phase three trial enrolled 610 adults in China with obesity or overweight. Primary weight endpoints were assessed at week 32. [1]
32-week endpoints; 48-week follow-up
Mazdutide groups lost more weight than placebo, with additional follow-up through week 48. The most frequently reported adverse events were gastrointestinal, generally mild or moderate. [1]
Compare like with like
Findings should retain their population, duration, and study conditions. Comparing headline percentages from unrelated trials cannot establish a winner, and regulatory decisions must be checked separately for each jurisdiction. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Ji et al. (2025): Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight →Receptor targets, Chinese study population, 610 participants, week-32 primary endpoints, week-48 findings, and adverse events.
